Skip to main content
Figure 2 | Acta Neuropathologica Communications

Figure 2

From: Systemic delivery of P42 peptide: a new weapon to fight Huntington’s disease

Figure 2

Pharmacokinetics of P42-TAT in the brain. A- MALDI-MS analysis (ranging from 699 to 4013 m/z) of mice brain soluble extract before (control), immediately (t0), or after 1 hour (t1h) and 3 hours (t3h) of incubation with 15 μg of P42-TAT peptide. Entire P42-TAT corresponds to m/z 3879.95 at t0. A m/z 1801.84 derivative is detected at t1h and t3h (*) B- The distribution of 30 P42-TAT putative derivatives selected have been analysed after IMS and TissueView processing from wild-type mice injected by ICV, or treated with empty NP, or with NP42T microemulsions, as indicated. This allowed to identify one major product, visualized on the brain section image and on the graph (ranging from 1796 to 1808 m/z). Red dot corresponds to the m/z 1801.84 derivative of P42, suggesting that this product is still present in the brain, 3 hrs after the Aonys® administration.

Back to article page